43.50
-0.37 (-0.84%)
| Previous Close | 43.87 |
| Open | 43.90 |
| Volume | 142,886 |
| Avg. Volume (3M) | 758,155 |
| Market Cap | 4,016,977,152 |
| Price / Sales | 7.35 |
| Price / Book | 11.77 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | -106.93% |
| Operating Margin (TTM) | -94.62% |
| Diluted EPS (TTM) | -6.46 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 257.89% |
| Current Ratio (MRQ) | 2.81 |
| Operating Cash Flow (TTM) | -418.59 M |
| Levered Free Cash Flow (TTM) | -231.16 M |
| Return on Assets (TTM) | -24.12% |
| Return on Equity (TTM) | -289.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.62% |
| % Held by Institutions | 97.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alkeon Capital Management Llc | 30 Sep 2024 | 3,011,716 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 121.00 (Canaccord Genuity, 178.16%) | Buy |
| Median | 95.00 (118.39%) | |
| Low | 73.00 (TD Cowen, 67.82%) | Buy |
| Average | 96.00 (120.69%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 48.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 95.00 (118.39%) | Buy | 43.50 |
| 06 Nov 2024 | 95.00 (118.39%) | Buy | 50.52 | |
| Wells Fargo | 20 Dec 2024 | 88.00 (102.30%) | Buy | 44.22 |
| JP Morgan | 21 Nov 2024 | 102.00 (134.48%) | Buy | 46.02 |
| Canaccord Genuity | 12 Nov 2024 | 121.00 (178.16%) | Buy | 47.84 |
| 06 Nov 2024 | 121.00 (178.16%) | Buy | 50.52 | |
| Cantor Fitzgerald | 06 Nov 2024 | 116.00 (166.67%) | Buy | 50.52 |
| 22 Oct 2024 | 116.00 (166.67%) | Buy | 54.79 | |
| RBC Capital | 06 Nov 2024 | 77.00 (77.01%) | Buy | 50.52 |
| 26 Sep 2024 | 77.00 (77.01%) | Buy | 55.22 | |
| TD Cowen | 21 Oct 2024 | 73.00 (67.82%) | Buy | 54.46 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |